Vorapaxar, a platelet thrombin-receptor antagonist, in medically managed patients with non-ST-segment elevation acute coronary syndrome: Results from the TRACER trial

European Heart Journal: Acute Cardiovascular Care

Volumn 3, Issue 3, 2014, Pages 246-256

  Held, Claes ^a   Tricoci, Pierluigi ^b   Huang, Zhen ^b   Van de Werf, Frans ^c   White, Harvey D ^d   Armstrong, Paul W ^e   Ambrosio, Giuseppe ^f   Aylward, Philip E ^g   Moliterno, David J ^h   Wallentin, Lars ^a   Chen, Edmond ⁱ   Erkan, Aycan ^j   Jiang, Lixin ^k   Strony, John ^l   Harrington, Robert A ^m   Mahaffey, Kenneth w ^m  

^a UPPSALA CLINICAL RESEARCH CENTER   (Sweden)

^b DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF LEUVEN   (Belgium)

^d AUCKLAND CITY HOSPITAL   (New Zealand)

^e UNIVERSITY OF ALBERTA   (Canada)

^f UNIVERSITY OF PERUGIA   (Italy)

^g FLINDERS UNIVERSITY   (Australia)

^h UNIVERSITY OF KENTUCKY   (United States)

ⁱ BAYER CORPORATION   (United States)

^j UFUK UNIVERSITY   (Turkey)

^k PEKING UNION MEDICAL COLLEGE   (China)

^l MERCK RESEARCH LABORATORIES   (United States)

^m STANFORD UNIVERSITY   (United States)

more..

Author keywords

Myocardial infarction; platelet receptor blockers; thrombosis

Indexed keywords

ANTITHROMBOCYTIC AGENT; LACTONE; PYRIDINE DERIVATIVE; VORAPAXAR;

ACUTE CORONARY SYNDROME; AGED; CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; HEMORRHAGE; HUMAN; MALE; MIDDLE AGED; MULTICENTER STUDY; MYOCARDIAL INFARCTION; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; RISK FACTOR; STROKE; TREATMENT OUTCOME;

ACUTE CORONARY SYNDROME; AGED; DOUBLE-BLIND METHOD; FEMALE; HEMORRHAGE; HUMANS; LACTONES; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PLATELET AGGREGATION INHIBITORS; PYRIDINES; RECURRENCE; RISK FACTORS; STROKE; TREATMENT OUTCOME;

EID: 84928704359     PISSN: 20488726     EISSN: 20488734     Source Type: Journal    
DOI: 10.1177/2048872614527838     Document Type: Article

References (16)

1. Hamm CW, Bassand JP, Agewall S, et al. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: the Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 2011; 32: 2999–3054.
2. Wright RS, Anderson JL, Adams CD, et al. 2011 ACCF/AHA focused update of the Guidelines for the Management of Patients with Unstable Angina/Non-ST-Elevation Myocardial Infarction (updating the 2007 guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines developed in collaboration with the American College of Emergency Physicians, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol 2011; 57: 1920–1959.
3. Roe MT, White JA, Kaul P, et al. Regional patterns of use of a medical management strategy for patients with non-STsegment elevation acute coronary syndromes: insights from the EARLY ACS Trial. Circ Cardiovasc Qual Outcomes 2012; 5: 205–213.
4. Goto K, Lansky AJ, Fahy M, et al. Predictors of outcomes in medically treated patients with acute coronary syndromes after angiographic triage: an Acute Catheterization And Urgent Intervention Triage Strategy (ACUITY) substudy. Circulation 2010; 121: 853–862.
5. Chan MY, Becker RC, Harrington RA, et al. Noninvasive, medical management for non-ST-elevation acute coronary syndromes. Am Heart J 2008; 155: 397–407.
6. Tricoci P, Huang Z, Held C, et al. Thrombin-receptor antagonist vorapaxar in acute coronary syndromes. N Engl J Med 2012; 366: 20–33.
7. TRA*CER Executive and Steering Committees. The Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRA*CER) trial: study design and rationale. Am Heart J 2009; 158: 327–334 e4.
8. Patel MR, Chen AY, Peterson ED, et al. Prevalence, predictors, and outcomes of patients with non-ST-segment elevation myocardial infarction and insignificant coronary artery disease: results from the Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA Guidelines (CRUSADE) initiative. Am Heart J 2006; 152: 641–647.
9. Bhatt DL, Roe MT, Peterson ED, et al. Utilization of early invasive management strategies for high-risk patients with non-ST-segment elevation acute coronary syndromes: results from the CRUSADE Quality Improvement Initiative. JAMA 2004; 292: 2096–2104.
10. Cohen MG, Filby SJ, Roe MT, et al. The paradoxical use of cardiac catheterization in patients with non-ST-elevation acute coronary syndromes: lessons from the Can Rapid Stratification of Unstable Angina Patients Suppress Adverse Outcomes With Early Implementation of the ACC/AHA Guidelines (CRUSADE) Quality Improvement Initiative. Am Heart J 2009; 158: 263–270.
11. Ottervanger JP, Armstrong P, Barnathan ES, et al. Association of revascularisation with low mortality in non-ST elevation acute coronary syndrome, a report from GUSTO IV-ACS. Eur Heart J 2004; 25: 1494–1501.
12. Becker RC, Bassand JP, Budaj A, et al. Bleeding complications with the P2Y 12 receptor antagonists clopidogrel and ticagrelor in the PLATelet inhibition and patient Outcomes (PLATO) trial. Eur Heart J 2011; 32: 2933– 2944.
13. Leonardi S, Tricoci P, White HD, et al. Effect of vorapaxar on myocardial infarction in the thrombin receptor antagonist for clinical event reduction in acute coronary syndrome (TRA-CER) trial. Eur Heart J 2013; 34: 1723–1731.
14. Yusuf S, Zhao F, Mehta SR, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001; 345: 494–502.
15. Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009; 361: 1045–1057.
16. Scirica BM, Bonaca MP, Braunwald E, et al. Vorapaxar for secondary prevention of thrombotic events for patients with previous myocardial infarction: a prespecified subgroup analysis of the TRA 2°P-TIMI 50 trial. Lancet 2012; 380: 1317–1324.